头孢曲松在预测肠杆菌科分离株对口服高级别头孢菌素的敏感性方面有多准确？
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
作者信息
Claeys Kimberly C, Simner Patricia J, Tekle Tsigereda, Harris Anthony D, Jacobs Emily, Cosgrove Sara E, Tamma Pranita D
机构信息
Department of Pharmacy Science and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0138724. doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.
Abstract
The reliability of ceftriaxone for inferring susceptibility to higher-generation oral cephalosporins is unknown. Overall, ceftriaxone susceptibility predicted susceptibility to cefuroxime (89%), cefdinir (86%), cefpodoxime (90%), and cefixime (94%) based on disk diffusion results for 409 consecutive Enterobacterales bloodstream isolates from unique patients. Susceptibility percentages to the four oral cephalosporins ranged from 92% to 99% when limited to , isolates susceptible to ceftriaxone.
摘要
头孢曲松用于推断对更高代口服头孢菌素敏感性的可靠性尚不清楚。总体而言，根据对409例来自不同患者的连续肠杆菌科血流分离株的纸片扩散结果，头孢曲松敏感性预测了对头孢呋辛（89%）、头孢地尼（86%）、头孢泊肟（90%）和头孢克肟（94%）的敏感性。当仅限于对头孢曲松敏感的分离株时，对四种口服头孢菌素的敏感率在92%至99%之间。
相似文献
1
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0138724. doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.
2
Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115299. doi: 10.1016/j.diagmicrobio.2020.115299. Epub 2021 Jan 15.
3
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in clinical isolates from the United States according to CLSI guidelines (2019-2021).
J Clin Microbiol. 2025 Jun 24:e0002725. doi: 10.1128/jcm.00027-25.
4
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369.
5
Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates.
J Med Microbiol. 2015 Oct;64(10):1170-1173. doi: 10.1099/jmm.0.000142. Epub 2015 Jul 23.
6
Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0125824. doi: 10.1128/aac.01258-24. Epub 2025 Jan 27.
7
In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
Int J Antimicrob Agents. 2023 Aug;62(2):106858. doi: 10.1016/j.ijantimicag.2023.106858. Epub 2023 May 19.
8
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
9
Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae.
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):75-80. doi: 10.1007/s10096-007-0402-5. Epub 2007 Oct 18.
10
Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.
PLoS One. 2014 Jan 31;9(1):e87849. doi: 10.1371/journal.pone.0087849. eCollection 2014.
引用本文的文献
1
Navigating the Muddled Middle: A Case-Based Exploration of Oral β-Lactams for Systemic Gram-Negative Infections.
Open Forum Infect Dis. 2025 Sep 3;12(9):ofaf435. doi: 10.1093/ofid/ofaf435. eCollection 2025 Sep.
本文引用的文献
1
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
Clin Infect Dis. 2024 Aug 7. doi: 10.1093/cid/ciae403.
2
Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales.
Open Forum Infect Dis. 2024 Jul 3;11(7):ofae377. doi: 10.1093/ofid/ofae377. eCollection 2024 Jul.
3
Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia.
JAMA Netw Open. 2024 Jan 2;7(1):e2352314. doi: 10.1001/jamanetworkopen.2023.52314.
4
Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections.
JAMA Netw Open. 2024 Jan 2;7(1):e2349864. doi: 10.1001/jamanetworkopen.2023.49864.
5
Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Clin Infect Dis. 2024 May 15;78(5):1103-1110. doi: 10.1093/cid/ciad703.
6
Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process.
Open Forum Infect Dis. 2021 Oct 11;8(10):ofab434. doi: 10.1093/ofid/ofab434. eCollection 2021 Oct.
7
Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections.
Int J Antimicrob Agents. 2021 Dec;58(6):106451. doi: 10.1016/j.ijantimicag.2021.106451. Epub 2021 Oct 20.
8
Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.
Expert Opin Pharmacother. 2019 Jun;20(8):903-907. doi: 10.1080/14656566.2019.1594774. Epub 2019 Mar 25.
9
A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455. doi: 10.1093/cid/ciz173.
10
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA Intern Med. 2019 Mar 1;179(3):316-323. doi: 10.1001/jamainternmed.2018.6226.
Zotero 插件